These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 9815953)

  • 1. Effect of ifosfamide treatment on glutathione and glutathione conjugation activity in patients with advanced cancers.
    Mulders TM; Keizer ; Ouwerkerk J; van der Velde EA; Breimer DD; Mulder GJ
    Clin Cancer Res; 1995 Dec; 1(12):1525-36. PubMed ID: 9815953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous ifosfamide/mesna is associated with depletion of plasma thiols without depletion of leukocyte glutathione.
    Pendyala L; Creaven PJ; Schwartz G; Meropol NJ; Bolanowska-Higdon W; Zdanowicz J; Murphy M; Perez R
    Clin Cancer Res; 2000 Apr; 6(4):1314-21. PubMed ID: 10778956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study of thiotepa in combination with the glutathione transferase inhibitor ethacrynic acid.
    O'Dwyer PJ; LaCreta F; Nash S; Tinsley PW; Schilder R; Clapper ML; Tew KD; Panting L; Litwin S; Comis RL
    Cancer Res; 1991 Nov; 51(22):6059-65. PubMed ID: 1933869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Variations in schedules of ifosfamide administration: a better understanding of its implications on pharmacokinetics through a randomized cross-over study.
    Brain EG; Rezai K; Weill S; Gauzan MF; Santoni J; Besse B; Goupil A; Turpin F; Urien S; Lokiec F
    Cancer Chemother Pharmacol; 2007 Aug; 60(3):375-81. PubMed ID: 17106751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ifosfamide-based drug combinations: preclinical evaluation of drug interactions and translation into the clinic.
    Vanhoefer U; Schleucher N; Klaassen U; Seeber S; Harstrick A
    Semin Oncol; 2000 Feb; 27(1 Suppl 1):8-13. PubMed ID: 10697038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In-transit melanoma: the role of alkylating-agent resistance in regional therapy.
    Grubbs EG; Abdel-Wahab O; Cheng TY; Abdel-Wahab Z; Peterson B; Pruitt SK; Colvin OM; Friedman HS; Tyler DS
    J Am Coll Surg; 2004 Sep; 199(3):419-27. PubMed ID: 15325612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of the glutathione enzyme system of human colon mucosa by localisation, gender and age.
    Hoensch H; Peters WH; Roelofs HM; Kirch W
    Curr Med Res Opin; 2006 Jun; 22(6):1075-83. PubMed ID: 16846540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glutathione transferase theta 1-1-dependent metabolism of the water disinfection byproduct bromodichloromethane.
    Ross MK; Pegram RA
    Chem Res Toxicol; 2003 Feb; 16(2):216-26. PubMed ID: 12588193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of ifosfamide on intracellular glutathione levels in peripheral blood lymphocytes and its correlation with therapeutic response in patients with advanced ovarian cancer.
    Malik IA; Mehboobali N; Iqbal MP
    Cancer Chemother Pharmacol; 1997; 39(6):561-5. PubMed ID: 9118472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of the effects of ifosfamide vs. mafosfamide treatment on intracellular glutathione levels and immunological functions of immunocompetent lymphocyte subsets.
    Botzler C; Kis K; Issels R; Multhoff G
    Exp Hematol; 1997 Apr; 25(4):338-44. PubMed ID: 9131009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Involvement of human glutathione S-transferase isoenzymes in the conjugation of cyclophosphamide metabolites with glutathione.
    Dirven HA; van Ommen B; van Bladeren PJ
    Cancer Res; 1994 Dec; 54(23):6215-20. PubMed ID: 7954469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glutathione conjugation of the cytostatic drug ifosfamide and the role of human glutathione S-transferases.
    Dirven HA; Megens L; Oudshoorn MJ; Dingemanse MA; van Ommen B; van Bladeren PJ
    Chem Res Toxicol; 1995; 8(7):979-86. PubMed ID: 8555414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of glutathione conjugation of melphalan in the isolated in situ liver perfusion in humans.
    Vahrmeijer AL; Snel CA; Steenvoorden DP; Beijnen JH; Pang KS; Schutrups J; Tirona R; Keizer HJ; van Dierendonck JH; van de Velde CJ; Mulder GJ
    Cancer Res; 1996 Oct; 56(20):4709-14. PubMed ID: 8840988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential catalytic efficiency of allelic variants of human glutathione S-transferase Pi in catalyzing the glutathione conjugation of thiotepa.
    Srivastava SK; Singhal SS; Hu X; Awasthi YC; Zimniak P; Singh SV
    Arch Biochem Biophys; 1999 Jun; 366(1):89-94. PubMed ID: 10334868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and pharmacodynamics of mesna-mediated plasma cysteine depletion.
    Smith PF; Booker BM; Creaven P; Perez R; Pendyala L
    J Clin Pharmacol; 2003 Dec; 43(12):1324-8. PubMed ID: 14615468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential roles of 3H-1,2-dithiole-3-thione-induced glutathione, glutathione S-transferase and aldose reductase in protecting against 4-hydroxy-2-nonenal toxicity in cultured cardiomyocytes.
    Li Y; Cao Z; Zhu H; Trush MA
    Arch Biochem Biophys; 2005 Jul; 439(1):80-90. PubMed ID: 15946642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brostallicin, a novel anticancer agent whose activity is enhanced upon binding to glutathione.
    Geroni C; Marchini S; Cozzi P; Galliera E; Ragg E; Colombo T; Battaglia R; Howard M; D'Incalci M; Broggini M
    Cancer Res; 2002 Apr; 62(8):2332-6. PubMed ID: 11956092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biochemical characterization of in vivo alkylating agent resistance of a murine EMT-6 mammary carcinoma. Implication for systemic involvement in the resistance phenotype.
    Chen G; Teicher BA; Frei E
    Cancer Biochem Biophys; 1998 Jun; 16(1-2):139-55. PubMed ID: 9923973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of N-acetylcysteine on ifosfamide-induced nephrotoxicity: in vitro studies in renal tubular cells.
    Chen N; Aleksa K; Woodland C; Rieder M; Koren G
    Transl Res; 2007 Jul; 150(1):51-7. PubMed ID: 17585863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abnormal glutathione conjugation in patients with tyrosinaemia type I.
    Mulders TM; Bergman DJ; Poll-The BT; Smit GP; Breimer DD; Mulder GJ; Duran M; Smeitink JA
    J Inherit Metab Dis; 1997 Aug; 20(4):473-85. PubMed ID: 9266383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.